布鲁顿酪氨酸激酶抑制剂治疗华氏巨球蛋白血症的研究进展  

Progress of Bruton’s tyrosine kinase inhibitors in the treatment of Waldenström Macroglobulinemia

作　　者：张睿 吴涛 周芮 Zhang Rui;Wu Tao;Zhou Rui(Department of Hematology,Center for Hematologic Diseases of Chinese PLA,the 940th Hospital of Joint Logistics Support force of Chinese People’s Liberation Army(Lanzhou Military Command General Hospital),Lanzhou 730050,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院(原兰州军区兰州总医院)全军血液病中心,兰州730050

出　　处：《国际遗传学杂志》2025年第1期38-44,共7页International Journal of Genetics

基　　金：甘肃省创新基地和人才计划(21JR7RA015);甘肃省重点研发计划(22YF7FA106);联勤保障部队第九四〇医院血液病医学研究中心项目(2021yxky078)。

摘　　要：华氏巨球蛋白血症(Waldenstr?m macroglobulinemia,WM)是一种罕见的惰性淋巴浆细胞性淋巴瘤,主要以淋巴浆细胞浸润骨髓和高表达单克隆免疫球蛋白M(immunoglobulin,IgM)为特征。布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase,BTK)属于非受体蛋白酪氨酸激酶Tec家族的成员之一,是B细胞受体信号通路的关键激酶,对B细胞的发育和存活至关重要。近年来,随着分子生物学研究的深入和药物研发的进步,BTK抑制剂在治疗WM中展现出显著疗效,为WM患者提供了新的治疗选择。本文就BTK在WM发病中的作用机制、BTK抑制剂治疗WM的研究进展进行综述。Waldenström macroglobulinemia(WM)is a rare inert lymphoplasmacytic lymphoma characterized primarily by lymphoplasmacytic infiltration of bone marrow and high expression of monoclonal immunoglobulin M(IgM).Bruton’s Tyrosine Kinase(BTK),a member of the Tec family of non-receptor protein tyrosine kinases,is a key kinase in the B-cell receptor signaling pathway and is essential for B-cell development and survival.In recent years,with the deepening of molecular biology research and the advancement of drug development,BTK inhibitors have demonstrated significant efficacy in the treatment of WM,providing new therapeutic options for WM patients.This article reviews the mechanism of action of BTK in the pathogenesis of WM and the research progress of BTK inhibitors in the treatment of WM.

关 键 词：华氏巨球蛋白血症 布鲁顿酪氨酸激酶 BTK抑制剂 治疗策略 

分 类 号：R733.1[医药卫生—肿瘤]